Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2011

Open Access 01-12-2011 | Primary research

Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter

Authors: Jessica T Li, Ka Bian, Alan L Zhang, Dong H Kim, William W Ashley, Rahul Nath, Ian McCutcheon, Bingliang Fang, Ferid Murad

Published in: Cancer Cell International | Issue 1/2011

Login to get access

Abstract

Objective

The objective of this study was to evaluate the anti-tumor effects of Ad/gTRAIL (an adenoviral vector in which expression of GFP and TRAIL is driven by a human telomerase reverse transcriptase promoter, hTERT) on malignant meningiomas and gliomas.

Background

Gliomas and meningiomas are the two most common types of human brain tumors. Currently there is no effective cure for recurrent malignant meningiomas or for gliomas. Ad/gTRAIL has been shown to be effective in killing selected lung, colon and breast cancer cells, but there have been no studies reporting its antitumor effects on malignant meningiomas. Therefore, we tested the antitumor effect of Ad/gTRAIL for the first time in human malignant meningioma and glioma cell lines, and in intracranial M6 and U87 xenografts.

Methods

Materials and Methods: Human malignant meningioma and glioma cells were infected with adenoviruses, Ad/gTRAIL and Ad/CMV-GFP. Cell viability was determined by proliferation assay. FACS analysis and quantification of TRAIL were used to measure apoptosis in these cells. We injected Ad/gTRAIL viruses in intracranial M6 and U87 xenografts, and measured the brain tumor volume, quantified apoptosis by TUNEL assay in the brain tumor tissue.

Results

Our studies demonstrate that in vitro/in vivo treatment with Ad/gTRAIL virus resulted in significant increase of TRAIL activity, and elicited a greater tumor cell apoptosis in malignant brain tumor cells as compared to treatment with the control, Ad/CMV-GFP virus without TRAIL activity.

Conclusions

We showed for the first time that adenovirus Ad/gTRAIL had significant antitumor effects against high grade malignant meningiomas as well as gliomas. Although more work needs to be done, our data suggests that Ad/gTRAIL has the potential to be useful as a tool against malignant brain tumors.
Appendix
Available only for authorised users
Literature
1.
Hoffman S, Propp JM, McCarthy BJ: Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol. 2006, 8 (1): 27-37. 10.1215/S1522851705000323.PubMedCentralCrossRefPubMed
2.
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002, 4 (4): 278-299.PubMedCentralPubMed
3.
Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP: Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther. 2002, 13 (9): 1015-1025. 10.1089/104303402753812421.CrossRefPubMed
4.
Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP: Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med. 2011, 11 (56): 46-56.PubMedCentralPubMed
5.
Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG: Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med. 2010, 10 (53): 293-304.PubMedCentralPubMed
6.
Hogg RT, Thorpe P, Gerard RD: Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther. 2011, 18 (4): 275-287. 10.1038/cgt.2010.78.PubMedCentralCrossRefPubMed
7.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266 (5193): 2011-2015. 10.1126/science.7605428.CrossRefPubMed
8.
Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, Sato N, Uchino J, Takayama K, Hashizume M: Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010, 294 (2): 178-186. 10.1016/j.canlet.2010.01.034.CrossRefPubMed
9.
Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, Takayama K, Matsumoto K, Hashizume M, Tanaka M: hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci. 2010, 101 (3): 735-742. 10.1111/j.1349-7006.2009.01445.x.CrossRefPubMed
10.
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000, 165 (5): 2886-2894.CrossRefPubMed
11.
Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature. 1990, 345 (6274): 458-460. 10.1038/345458a0.CrossRefPubMed
12.
Gu J, Andreeff M, Roth JA, Fang B: hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 2002, 9 (1): 30-37. 10.1038/sj.gt.3301619.CrossRefPubMed
13.
Bhardwaj A, Aggarwal BB: Receptor-mediated choreography of life and death. J Clin Immunol. 2003, 23 (5): 317-332. 10.1023/A:1025319031417.CrossRefPubMed
14.
Counter CM, Meyerson M, Eaton EN, Weinberg RA: The catalytic subunit of yeast telomerase. Proc Natl Acad Sci USA. 1997, 94 (17): 9202-9207. 10.1073/pnas.94.17.9202.PubMedCentralCrossRefPubMed
15.
Griffith TS, Broghammer EL: Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther. 2001, 4 (3): 257-266. 10.1006/mthe.2001.0439.CrossRefPubMed
16.
Ashkenazi A, Herbst RS: To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008, 118 (6): 1979-1990. 10.1172/JCI34359.PubMedCentralCrossRefPubMed
17.
Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998, 16 (9): 1217-1222. 10.1038/sj.onc.1201882.CrossRefPubMed
18.
Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 2001, 61 (15): 5796-5802.PubMed
19.
Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet. 1997, 6 (12): 2011-2019. 10.1093/hmg/6.12.2011.CrossRefPubMed
20.
Allshire RC, Dempster M, Hastie ND: Human telomeres contain at least three types of G-rich repeat distributed non-randomly. Nucleic Acids Res. 1989, 17 (12): 4611-4627. 10.1093/nar/17.12.4611.PubMedCentralCrossRefPubMed
21.
Fang B, Ji L, Bouvet M, Roth JA: Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem. 1998, 273 (9): 4972-4975. 10.1074/jbc.273.9.4972.CrossRefPubMed
22.
Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001, 61 (8): 3330-3338.PubMed
23.
Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B: Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol. 2003, 22 (6): 1241-1245.PubMed
24.
Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000, 60 (19): 5359-5364.PubMed
25.
Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, Fang B: Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 2002, 62 (13): 3620-3625.PubMed
26.
Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B: Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther. 2001, 3 (3): 278-283. 10.1006/mthe.2001.0273.CrossRefPubMed
27.
Gu J, Fang B: Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther. 2003, 2 (4 Suppl 1): S64-70.PubMed
28.
Li YM, Song ST, Jiang ZF, Zhang Q, Su CQ, Liao GQ, Qu YM, Xie GQ, Li MY, Ge FJ: Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. World J Gastroenterol. 2008, 14 (8): 1274-1279. 10.3748/wjg.14.1274.PubMedCentralCrossRefPubMed
29.
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6 (5): 564-567. 10.1038/75045.CrossRefPubMed
30.
Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B: Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene. 2002, 21 (52): 8020-8028. 10.1038/sj.onc.1205926.CrossRefPubMed
31.
Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S: Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol. 2007, 9 (3): 245-258. 10.1215/15228517-2007-012.PubMedCentralCrossRefPubMed
32.
Yu de B, Zhong SY, Yang M, Wang YG, Qian QJ, Zheng S, Liu XY: Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. Cancer Sci. 2009, 100 (4): 678-683. 10.1111/j.1349-7006.2009.01110.x.CrossRefPubMed
33.
34.
Blackburn EH: Structure and function of telomeres. Nature. 1991, 350 (6319): 569-573. 10.1038/350569a0.CrossRefPubMed
35.
Chen B, He C, Lao WF, Huang XF, Fang BL: [Activity of the TNF-related apoptosis-inducing ligand gene expressed from the hTERT promoter on colon cancer cell line HT-29]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006, 35 (1): 45-49.PubMed
36.
Mittereder N, March KL, Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996, 70 (11): 7498-7509.PubMedCentralPubMed
37.
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J: The RNA component of human telomerase. Science. 1995, 269 (5228): 1236-1241. 10.1126/science.7544491.CrossRefPubMed
38.
McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM, Fuller GN: Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg. 2000, 92 (2): 306-314. 10.3171/jns.2000.92.2.0306.CrossRefPubMed
Metadata
Title
Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter
Authors
Jessica T Li
Ka Bian
Alan L Zhang
Dong H Kim
William W Ashley
Rahul Nath
Ian McCutcheon
Bingliang Fang
Ferid Murad
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2011
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-11-35

Other articles of this Issue 1/2011

Cancer Cell International 1/2011 Go to the issue

Primary research

Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr

Primary research

Murine mammary tumor cells with a claudin-low genotype

Primary research

Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres

Primary research

MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines

Primary research

Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis

Primary research

Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits